Treating Hepatitis C in Patients with Renal Failure

Area of Science:

• Nephrology
• Hepatology
• Virology

Background:

• Hepatitis C virus (HCV) infection is closely linked to kidney disease, affecting 10-16% of patients and showing higher prevalence in those with renal dysfunction.
• HCV-positive patients on hemodialysis (HD) face increased mortality from liver and cardiovascular complications.
• Previous interferon-based treatments for HCV in HD patients were limited by adverse events like anemia and infections.

Purpose of the Study:

• To evaluate the efficacy and safety of direct-acting antivirals (DAAs) for treating HCV in patients with end-stage renal disease (ESRD).
• To assess the impact of DAAs on viral eradication and patient outcomes in a vulnerable population.

Main Methods:

• Review of two clinical trials (C-SURFER and RUBY-I) assessing DAA regimens in ESRD patients.
• Analysis of sustained virological response (SVR) rates and adverse events associated with DAA therapy.
• Consideration of real-world data for specific drugs like sofosbuvir in patients with impaired kidney function.

Main Results:

• The grazoprevir/elbasvir combination achieved 94% SVR in the C-SURFER trial with mild adverse events.
• The 3D regimen demonstrated a 90% SVR rate in 20 ESRD patients in the RUBY-I trial.
• Real-world data suggest favorable efficacy and safety for sofosbuvir, despite renal elimination concerns.

Conclusions:

• Direct-acting antivirals (DAAs) provide a safe and highly effective treatment option for HCV in patients with renal dysfunction.
• DAA therapy has revolutionized HCV management, enabling viral eradication in patients with ESRD and those on hemodialysis.